Skip to main content
. 2023 Dec 26;23(2):100707. doi: 10.1016/j.mcpro.2023.100707

Fig. 8.

Fig. 8

Kinase activity analysis identifies EGFR hyperactivation as a new target in poor-prognosis liver cancer.A, scatterplot comparing hazard ratios of kinase activities inferred based on DeepRescore2-and PhosphoRS-derived data, respectively. B, Kaplan Meier curves for patients stratified based on median abundance of EGFR activity inferred based on PhosphoRS-derived data. C, Kaplan Meier curves for patients stratified based on median abundance of EGFR activity inferred based on DeepRescore2-derived data. D, correlation between afatinib response quantified based on AUC and EGFR_Y1068 abundance measured by RPPA. E, Western blot analysis of EGFR_Y1068 on three HCC organoids, HCCO7, HCCO5, and HCCO31, treated with DMSO or 5 μM afatinib for 2 h. F, relative cell viability as a function of afatinib concentration in the three organoids. Data were from three replicates.